This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal

JOHN H. MOYER, M.D.; GEORGE C. MORRIS, Jr., M.D.; CARROLL A. HANDLEY, M.D.; BARTIS KENT, M.D.; WILLIAM MATHEWS, M.D.

AMA Arch Intern Med. 1954;94(3):497-502.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

CHLORPROMAZINE (10-[y - dimethylaminopropyl] - 2 - chlorophenothiazine hydrochloride) is a new drug that effectively protects dogs from apomorphineinduced emesis and motion sickness.* It acts by depressing the emetic chemoreceptor trigger zone and the vomiting reflex site within the central nervous system.³ Laboratory toxicity studies indicated that chlorpromazine is relatively safe for use in man.⁴ Therefore, we undertook a further evaluation of hemodynamic and toxicological effects in dogs and in man. These are briefly summarized in Figure 2.

Upon completion of the hemodynamic and toxicity studies, an effort was made to evaluate the clinical effectiveness of chlorpromazine as an antiemetic. These observations are briefly summarized in Figures 3 to 5. The chlorpromazine was administered to patients with persistent vomiting who had failed to respond to commonly employed antiemetic measures and had become definite therapeutic problems. In each patient, the cause of nausea and vomiting has been reasonably well established before starting . . . [Full Text PDF of this Article]

Author Affiliations
HOUSTON, TEXAS

From Baylor University College of Medicine and Jefferson Davis Hospital.

Footnotes
Shown as a scientific exhibit of the Section on Experimental Medicine and Therapeutics at the 103rd Annual Meeting of the American Medical Association, San Francisco, June 21-25, 1954.